Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 11:55 ET | Source: Research and Markets

Global Interventional Oncology Industry Set to Grow by $1.18 Billion During 2026-2030 - AI-Assisted Imaging and Minimally Invasive Procedures Drive Interventional Oncology Expansion

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market...
March 27, 2026 11:12 ET | Source: Research and Markets

Competitive Insights and Expert Consultation on the Growing Oncology Nutrition Market, 2026-2030: A $3.27 Billion Opportunity

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology nutrition market has shown robust...
March 03, 2026 07:35 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven...
December 17, 2025 04:12 ET | Source: Research and Markets

Hepatology Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Dublin, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The "Hepatology Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030" has been added to ResearchAndMarkets.com's...
July 07, 2025 07:30 ET | Source: Yiviva

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025

YIV-906, in combination with sorafenib, shows promising Phase 2b results for advanced liver cancer, enhancing efficacy and reducing toxicity.
April 25, 2025 09:35 ET | Source: Research and Markets

The Global Market for Interventional Oncology Devices 2025-2030 - Rising Focus on Targeted Cancer Therapies Expands Addressable Market for Interventional Devices

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for...
February 27, 2025 11:08 ET | Source: Research and Markets

Interventional Oncology Research Report 2025: Devices & Consumables, Procedures, Cancer, End User Market Analysis and Forecasts 2024-2029

Dublin, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Devices & Consumables (RF, Microwave, Cryoablation. Embolization), Procedures (Thermal Ablation, Non-Thermal...
May 30, 2024 07:00 ET | Source: Elevar Therapeutics

Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma

Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
January 18, 2024 08:45 ET | Source: Elevar Therapeutics

Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium

A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
October 23, 2023 08:45 ET | Source: Elevar Therapeutics

Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

FORT LEE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...